华森制药(002907) - 2024年7月24日投资者关系活动记录表

Financial Performance - In Q1 2024, the company achieved a revenue of 228 million CNY, a year-on-year increase of 21.78% due to strong growth in traditional Chinese medicine products, with the top five exclusive traditional Chinese medicines' revenue increasing by 34.61% [2] - The net profit attributable to shareholders was 40.35 million CNY, up 34.05% year-on-year, while the net profit excluding non-recurring items was 37.26 million CNY, an increase of 30.41% [2] - Basic earnings per share increased by 33.98% compared to the same period last year, driven by increased gross profit from core business revenue [3] Market Strategy and Product Development - The company is actively adjusting its product structure and increasing R&D investment to adapt to industry changes, aiming to create new performance growth points through innovative products [3] - The global market for specialized medical foods is approximately 3 billion USD, with China's market size around 7 billion CNY, indicating significant growth potential [4] - The company has established the first specialized medical food production base in the Sichuan-Chongqing region, expected to obtain its first production license by the end of 2024 [4] Supply Chain Management - To address rising costs of traditional Chinese medicine materials, the company conducts in-depth market research to ensure a stable supply chain and flexible procurement strategies [3] - The company employs a strategy of small-batch procurement to mitigate inventory risks and control costs, while continuously optimizing procurement cycles [3] Innovation and R&D - The company has five self-developed innovative drug projects in the oncology field, with ongoing patent applications and research progress aligning with expectations [5] - In 2023, the company applied for six innovative drug compound patents, with a total of 13 patents filed to date [5] Response to Market Challenges - The company acknowledges the significant impact of centralized procurement on existing products but sees limited effects on new products [5] - Strategies include exploring diversified development in advantageous areas, expanding market channels, and continuously launching new products to drive revenue growth [5] Sales Channels - The company's sales are primarily focused on public hospitals, with approximately 70% of sales occurring in this sector, while also expanding into e-commerce and new media channels [6]